Posted on

Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results for Reproxalap at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting

Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results for Reproxalap at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting
LEXINGTON, Mass., May 1, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, presented ... .... ( read more )
Orginally Published At: Drugs – Clinical Trials